<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659759</url>
  </required_header>
  <id_info>
    <org_study_id>20F.1043</org_study_id>
    <nct_id>NCT04659759</nct_id>
  </id_info>
  <brief_title>COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes</brief_title>
  <acronym>COVID-PRICE</acronym>
  <official_title>COVID-19 in Pregnancy: Utilizing Immunology Through Epidemiology to Improve Perinatal/Neonatal Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nemours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study of pregnant patients at an urban academic center diagnosed&#xD;
      with perinatal COVID-19 infection, followed up to 6 weeks postpartum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal aims to provide a multi-faceted approach to addressing perinatal COVID-19&#xD;
      infection by (1) improving our understanding of SARS-CoV-2 antibody specificity and&#xD;
      durability over the course of pregnancy/postpartum in mother/baby dyad (2) understanding the&#xD;
      downstream implications of maternal systemic inflammatory response with COVID-19 infection&#xD;
      through study of fetal inflammatory response, placental pathology, and perinatal outcomes,&#xD;
      and (3) to evaluate the interplay between socioeconomic characteristics, COVID-19, and early&#xD;
      neonatal outcomes. (4) Evaluate antibody generation and durability in pregnant/breastfeeding&#xD;
      women who receive any form of the COVID-19 vaccine&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal COVID-19 serology (IgG and IgM)</measure>
    <time_frame>6 weeks post partum</time_frame>
    <description>IgG/IgM time profile through pregnancy up to 6 weeks post partum for those exposed to COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal/neonatal IgG and IgM concordance</measure>
    <time_frame>Delivery</time_frame>
    <description>IgG/IgM at delivery in mother/neonate through maternal and cord blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal COVID serology time/profile following vaccination</measure>
    <time_frame>6 months</time_frame>
    <description>Baseline, 1m, 3m, 6m post second vaccine dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breastmilk Serology</measure>
    <time_frame>6months</time_frame>
    <description>Breastmilk IgG and IgA time profile following COVID vaccine in breastfeeding women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breastmilk Serology</measure>
    <time_frame>Delivery</time_frame>
    <description>COVID-19 IgG and IgA in breast milk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastmilk Serology</measure>
    <time_frame>6 weeks post partum</time_frame>
    <description>COVID-19 IgG and IgA in breastmilk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine</measure>
    <time_frame>Delivery</time_frame>
    <description>Compare maternal COVID (+) and COVID (-) cytokine panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal cytokine</measure>
    <time_frame>Delivery</time_frame>
    <description>Compare cordblood cytokine panel between COVID(+) and COVID (-) at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID disease vs vaccination immune response</measure>
    <time_frame>6 months</time_frame>
    <description>Compare maternal IgG concentration time/profile in those with COVID disease vs COVID vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID vaccine in pregnant vs nonpregnant</measure>
    <time_frame>6 months</time_frame>
    <description>Compare maternal IgG concentration/time profile in pregnant vs non-pregnant women with vaccine</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 Positive</arm_group_label>
    <description>Patients diagnosed with COVID-19 during pregnancy or while breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 vaccine</arm_group_label>
    <description>Patients who receive COVID-19 vaccine during pregnancy or while breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Reproductive age women exposed to COVID-19 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant Control</arm_group_label>
    <description>Pregnant women who delivered at TJUH, COVID negative</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COVID-19 exposure</intervention_name>
    <description>COVID-19 exposure during pregnancy</description>
    <arm_group_label>COVID-19 Positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccine</intervention_name>
    <description>Receipt of any COVID-19 vaccine</description>
    <arm_group_label>COVID-19 vaccine</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Maternal serum/plasma&#xD;
&#xD;
             -  SARS-CoV-2 serology&#xD;
&#xD;
             -  Cytokine/chemokine panel&#xD;
&#xD;
        -  Cord blood serum/plasm&#xD;
&#xD;
             -  SARS-CoV-2 serology&#xD;
&#xD;
             -  Cytokine/chemokine panel&#xD;
&#xD;
             -  DNA methylation, miRNA/mRNA exression&#xD;
&#xD;
        -  Breastmilk o SARS-CoV-2 serology&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients diagnosed with COVID-19 at any point during pregnancy or within 6 weeks&#xD;
        post partum&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of COVID-19 in pregnancy or within 6 months post partum&#xD;
&#xD;
          -  Planned delivery at Thomas Jefferson University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Declines routine COVID testing on admission&#xD;
&#xD;
          -  In active labor/pain/otherwise unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupsa C Boelig, MD</last_name>
      <phone>215-955-9196</phone>
      <email>rupsa.boelig@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

